|
| ||
| ACHING FEET Sep 15, 2004 RE ACETYL L CARNITINE i have taken ddi & d4t over 10 yrs ago & since then had neuropathy in feet,just stiff, not too bad, until last year when it got worse; i tried amiltryptiline, patches & neurontin, without help; so i took morphine which killed the pain , but trying to lower it and now i am starting alc, seeing the results of the study of dr youle of london, which gave good results; whats your experience with this product in the us?? any info welcome also from patients having neuropathy; my email is dukmenen@hotmail.com thks herb in belgium |
||||||||||
|
|
Response from Dr. Henry
The results you mentioned were recently published in AIDS from a pilot study using I believe 1500 mg acetyl L carnitine. I have only had a few patients take that drug at that dose so I cannot comment from my personal experience. There was no control group so the study should be viewed as a pilot study that needs to be confirmed. The ACTG in the US is doing a dose rangeing study I think which starts at 500 mg BID up to 1500 mg BID. There is also a prosaptide 0 study in the US and a high strength topical capsaicin study that are open or soon to open. Stopping offending meds and getting evaluated for other contributing factors is also wise. It is encouraging to see some new and possibly effective treatments being evaluated for HIV related peripheral neuropathy. KH | |||||||||
Get Email Notifications When This Forum Updates or Subscribe With RSS
|
||||||||||
Q&A TERMS OF USE
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.
Review our complete terms of use and copyright notice.










